Effect of Pro12Ala polymorphism of PPARG gene on lipid peroxidation and antioxidant defense in patients with type 2 diabetes depending on the duration of the disease

Authors

  • V. Y. Mokrii O.O. Bogomolets National Medical University,
  • S. V. Ziablytsev O.O. Bogomolets National Medical University,

DOI:

https://doi.org/10.14739/2310-1237.2016.2.81332

Keywords:

Pro12Ala polymorphism of PPARG gene, type 2 diabetes, oxidative stress

Abstract

Aim – to study the impact of polymorphic marker rs1801282 of gene PPARG on the formation of oxidative stress in terms of LPO and AOS in patients with type 2 diabetes depending on the duration of the disease.

Materials and methods. The study was conducted involving 138 patients, 88 of whom were patients with type 2 diabetes and the control group consisted of 50 people. Patients were divided into three groups according to disease duration: 5 years, 5-10 years and more than 10 years. LPO activity was assessed in terms of diene conjugates (DC) and malonic dialdehyde (MDA) and AOC status - the activity of superoxide dismutase (SOD), catalase and the level of α-tocopherol (α-TF). Molecular genetic studies were conducted by the method of PCR in real time, and to analyze polymorphic DNA loci a standardized test system TaqMan Mutation Detection Assays Life-Technology (USA) was used.

Results. During 5-10 years disease levels of DC and MDA in patients with Pro12Ala genotype were increased by 34,9% and 34,7%, as compared to Pro12Pro (p=0,01). Availability of Pro12Pro stipulated the reduction of catalase activity during 5-10 years disease by 75% (p=0,001), and for those, who are ill for more than 10 years by 2,04 times (p=0,01), which is not different from the reference level (F=1,19; p=0,600), but in the case of Pro12Ala, this figure was 2 times higher.

Conclusions. Pro12Ala polymorphism (rs1801282) of PPARG gene causes the development of oxidative stress in type 2 diabetes with 5-10 years durations, and genotype Pro12Pro - lack of the catalase enzyme level of antioxidant system in patients with durations of disease more than 5 years.

References

PankIv, V. I. (2015). Shliakhy udoskonalennia taktyky nadannia dopomohy khvorym na tsukrovyi diabet v ambulatornykh umovakh (farmakoepidemiolohichnyi pidkhid) [Ways of improving tactics to assist people with diabetes in an outpatient setting (pharmacoepidemiological approach)]. Zdorovia Ukrainy XXI storichchia, 1, 23–24. [in Ukrainian].

Zhurakivska, O. Ya., Tytyk, V. V., Zhurakivska, V. M., & Pertsovich, V. M. (2014) Rol protsesiv perokysnoho okyslennia lipidiv u rozvytku diabetychnykh mikroanhiopatii [The role of lipid peroxidation in the development of diabetic microangiopathy]. Zdobutky klinichnoi i eksperymentalnoi medytsyny, 12, 232. [in Ukrainian].

Sorokina, Yu. A., & Lovcova, L. V. (2015). Koe´fficienty okislitel´nogo stressa kak sposob personificirovaniya farmakoterapii v debyute SD 2 tipa [Odds of oxidative stress as a way of personification of pharmacotherapy in type 2 diabetes debut]. Universum: Medicina i farmakologiya, 1(14). Retrived from: http://7universum.com/ru/med/archive/item/1868. [in Russian].

Bandeira, Sde M., Guedes, Gda S., da Fonseca, L. J., Pires, A. S., Gelain, D. P., Moreira, J. C., et al. (2012). Characterization of blood oxidative stress in type 2 diabetes mellitus patients: increase in lipid peroxidation and SOD activity. Oxid Med. Cell Longev. Retrived from: http: //www.ncbi.nlm.nih.gov/pmc/articles/PMC3509371/pdf/. doi: 10.1155/2012/819310.

Bondar', I. A., Filipenko, M. L., Shabel'nikova, O. Yu.,& Sokolova, E. A. (2013). Associaciya polimorfnykh markerov rs7903146 gena TCF7L2 i rs1801282 gena PPARG [Pro12Ala] s sakharnym diabetom 2 tipa v Novosibirskoj oblasti [Rs7903146 variant of TCF7L2 gene and rs18012824 variant of PPARG2 gene (Pro12Ala) are associated with type 2 diabetes mellitus in Novosibirsk population]. Sakharnyj diabet, 4, 17–22. [in Russian].

Ziablytsev, S. V., & Mokrii, V. Y. (2016). Asotsiatsiia alelia 12Pro polimorfizmu rs1801282 hena PPARG z tsukrovym diabetom 2 typu [Association between allele 12Pro of rs1801282 polymorphism gene PPAR and diabetes mellitus type 2]. Klinichna endokrynolohiia ta endokrynna khirurhiia, 3(55), 34–38 [in Ukrainian].

Liu, L., Zheng, T., Wang, F., Wang, N., Song, Y., Li, M., et al. (2010). Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care, 33(1), 144–149. doi: 10.2337/dc09-1258.

Ivanova, E. A., Parolari, A., Myasoedova, V., Melnichenko, A. A., Bobryshev, Y. V., & Orekhov, A. N. (2015). Peroxisome proliferator-activated receptor [PPAR] gamma in cardiovascular disorders and cardiovascular surgery. J Cardiol., 66(4), 271–278. doi: 10.1016/j.jjcc.2015.05.004.

Chao, C. T., Chen, Y. C., Chiang, C. K., Huang, J. W., Fang, C. C., Chang, C. C., & Yen, C. J. (2016). Interplay between Superoxide Dismutase, Glutathione Peroxidase, and Peroxisome Proliferator Activated Receptor Gamma Polymorphisms on the Risk of End-Stage Renal Disease among Han Chinese Patients. Oxid Med Cell Longev. ID 8516748, doi: 10.1155/2016/8516748.

Ziablytsev, S. V., Mokrii,V. Y., & Crystal, M. V. (2016) The value of polymorphism RRO12ALA gene PPARG in violation of lipid peroxidation and antioxidant protection in patients with type 2 diabetes mellitus. Journal of Education, Health and Sport, 6(9), 626–636. doi: http://dx.doi.org/10.5281/zenodo.158861.

Titc, N. U. (Ed.) (1997) E´ncyclopedia clinicheskikh laboratornykh testov [Encyclopedia of clinical laboratory tests]. Moscow: Labinform. [in Russian].

How to Cite

1.
Mokrii VY, Ziablytsev SV. Effect of Pro12Ala polymorphism of PPARG gene on lipid peroxidation and antioxidant defense in patients with type 2 diabetes depending on the duration of the disease. Pathologia [Internet]. 2016Oct.27 [cited 2024Apr.21];13(2). Available from: http://pat.zsmu.edu.ua/article/view/81332

Issue

Section

Original research